Inhibitory Receptors in Eosinophils of Atopic Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01489293
Recruitment Status : Completed
First Posted : December 9, 2011
Last Update Posted : March 22, 2018
Information provided by (Responsible Party):
Meir Medical Center

Brief Summary:
The purpose of this study is to analyze the expression and activity of inhibitory molecules on eosinophils obtained from allergic subjects.

Condition or disease
Atopy Atopic Dermatitis Asthma Allergic Rhinitis Food Allergy

Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Case-Control
Time Perspective: Other
Official Title: Characterization of the Expression and Activity of Inhibitory Receptors Such as CLM-1 in Eosinophils of Atopic Subjects
Actual Study Start Date : May 1, 2012
Actual Primary Completion Date : December 31, 2013
Actual Study Completion Date : December 31, 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

atopic subjects
Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
non-atopic subjects
Control group without atopic diseases.

Primary Outcome Measures :
  1. Expression of surface molecules on eosinophils as assessed by flow cytometry [ Time Frame: December 2013 ]
    Blood samples from donors will be stained and evaluated by flow cytomtery

Biospecimen Retention:   Samples With DNA
whole blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
allergy clinic

Inclusion Criteria:

  • age 20-60 years
  • a physician-diagnosed atopic disease

Exclusion Criteria:

  • atopic disease not active
  • steroid treatment
  • active non-atopic inflammatory disease, including infections
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01489293

Meir Medical Center. Unit of Allergy and Clinical Immunology
Kfar Saba, Israel
Sponsors and Collaborators
Meir Medical Center
Principal Investigator: Alon Y Hershko, MD, PhD Meir Medical Center

Responsible Party: Meir Medical Center Identifier: NCT01489293     History of Changes
Other Study ID Numbers: MMC110053CTIL
First Posted: December 9, 2011    Key Record Dates
Last Update Posted: March 22, 2018
Last Verified: March 2018

Additional relevant MeSH terms:
Rhinitis, Allergic
Dermatitis, Atopic
Food Hypersensitivity
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Skin Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous